We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Genetic Risk Factor for Premature Birth Found

By LabMedica International staff writers
Posted on 22 May 2014
Image: The iQ5 real-time polymerase chain reaction (PCR) detection system (Photo courtesy of Bio-Rad).
Image: The iQ5 real-time polymerase chain reaction (PCR) detection system (Photo courtesy of Bio-Rad).
A genetic risk factor for premature birth has been discovered and it is related to a gene that codes for a protein that the scientists have found helps the body’s immune cells recognize and fight group B streptococcal (GBS) bacteria.

These GBS bacteria also known as Streptococcus agalactiae, are found in the vagina or lower gastrointestinal tract of approximately 15% to 20% of healthy women, but may cause life-threatening infections, such as sepsis or meningitis in newborns, especially those born prematurely.

Scientists at University of California, San Diego (La Jolla, CA, USA) and their international collaborators, studied a pair of proteins that together helps balance the body’s immune response to pathogens, by directing some antimicrobial response without provoking excessive inflammation. They isolated neutrophils from whole blood from three to six different donors per genotype. Freshly isolated sterile human placentas obtained from caesarian section were used for preparation of amniotic epithelial membranes (AM).

The investigators performed gene expression analysis, cytokine secretion, and cell signaling studies. Real-time polymerase chain reaction (PCR) was performed on an iQ5 machine (Bio-Rad Laboratories; Hercules, CA, USA) and cytokines in culture supernatants were quantitated using enzyme-linked immunosorbent assay (ELISA) kits (R&D Systems; Minneapolis, MN, USA). Paraffin sections were deparaffinized, blocked for endogenous nonspecific sites, and stained with human anti-sialic acid-binding immunoglobulin-like lectin 5 (Siglec-5) and anti–Siglec-14 antibodies.

The team found that the protein Siglec-5 binds to the GBS pathogen and suppresses immune response to the microbe, while the other protein, Siglec-14, binds to the pathogen, and activates killing of the bacteria. These sialic acid-binding immunoglobulin-type lectins are cell surface receptors found typically on immune cells. They recognize and bind sialic acids, which are sugar molecules that densely coat cells. The gene for Siglec-14 is missing in some individuals, and the investigators have found that fetuses that lack the Siglec-14 protein are at higher risk of premature birth, likely due to an imbalanced immune response to the bacterial infection.

Victor Nizet, MD, professor of pediatrics and pharmacy and coauthor of the study said, “Pregnant women are universally screened for these bacteria during pregnancy and administered antibiotics intravenously during labor if they test positive to protect the infant from infection. Our study may explain why some women and their infants are at higher risk of acquiring severe GBS infections than others.” The study was published on May 5, 2014, in the Journal of Experimental Medicine.

Related Links:

University of California, San Diego
Bio-Rad Laboratories 
R&D Systems


Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
New
Gold Member
Automatic Hematology Analyzer
CF9600
New
All-in-One Molecular System
AIO M160
New
Benchtop Thermomixer
Biometra TS1 ThermoShaker

Channels

Clinical Chemistry

view channel
Image: Plasma pTau217 testing can predict future amyloid accumulation and cognitive decline in cognitively healthy older adults (photo courtesy of Shutterstock)

Blood Test Predicts Alzheimer Disease Risk Before Imaging Changes and Symptoms

Alzheimer's disease often advances silently for years, making timely risk stratification difficult in routine practice. Current approaches to detect pathology can involve lumbar puncture or positron emission... Read more

Industry

view channel
Image: The GenoPredict assay from Predicta Biosciences is available to Tempus Life Sciences partners to support exploratory research and clinical development programs (photo courtesy of Shutterstock)

Partnership Expands Ultrasensitive WGS Assay for for Hematologic Malignancies and MRD Monitoring

Tempus AI and Predicta Biosciences announced the commercial expansion of a co-branded whole‑genome sequencing assay GenoPredicta, which is intended for comprehensive genomic characterization of hematologic... Read more